

## *Curriculum Vitae*

**Nicolas Kahn** Dr. med.  
d.o.b. June 27th, 1982, in Buenos Aires, Argentina

### **University Education**

2012 Doctorate Medicine, University of Heidelberg  
2001–2008 Studies of Medicine, University of Heidelberg Medical School, Mount Sinai Hospital New York, USA

### **Scientific Career**

2021 DZL Principal Investigator Disease Area Diffuse Parenchymal Lung Disease  
2015-2018 ERS Early Career Members Committee (ECMC) Representative for the Science Council  
Since 2012 Member of the „Translational Research Center Heidelberg“ (TLRC) with focus on the Disease Areas DPLD, Lung Cancer and COPD  
Since 2007 Member of the Translational Research Unit, Thoraxklinik Heidelberg University Hospital

### **Awards and Honors**

2016 GlaxoSmithKline-Science Award for Clinical Pneumology  
2013 Travel-Grant from the GSK-foundation for the IASLC Meeting in Sydney, Australia  
2012 “Ludolf-Krehl-Award” from the “Südwestdeutschen Gesellschaft für Innere Medizin” for the doctoral thesis  
2001 Travel-Grant from the Klaus Tschira Foundation “International Summer Science Institute” (ISSI) at the Weizmann Institute of Science, Rehovot, Israel

### **Citation Record**

*Total citations: 2135; h-index:16;* (ResearchGate August 5<sup>th</sup>, 2022)

## Top-10 selected Publications

Trinkmann F, Müller M, Reif A, **Kahn N**, Kreuter M, Trudzinski F, Eichinger M, Heussel CP, Herth FJF; Lung Network Rhine-Neckar-Region. Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. **Eur Respir J** 2021 Feb 25;57(2):2003002.

Veith C, Hristova M, Danyal K, Habibovic A, Dustin CM, McDonough JE, Vanaudenaerde BM, Kreuter M, Schneider MA, **Kahn N**, van Schooten FJ, Boots AW, van der Vliet A. Profibrotic epithelial TGF- $\beta$ 1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. **Am J Physiol Lung Cell Mol Physiol**. 2021 Mar 1;320(3):L356-L367.

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagemeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, **Kahn N**, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. **Eur Respir J** 2020 Aug 13;56(2):1902279.

Lukassen S, Chua RL, Trefzer T, **Kahn N**, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. **EMBO J**. 2020 May 18;39(10):e105114

Torrise SE, **Kahn N**, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. **BMC Pulm Med**. 2019 Nov 12;19(1):213.

Kreuter M, Lederer DJ, Cottin V, **Kahn N**, Ley B, Vancheri C, Weycker D, Atwood M, Kirchgassler KU, Ryerson CJ. Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. **Eur Respir J**. 2019 Dec 12;54(6):1901188

**Kahn N**, Rossler AK, Hornemann K, Muley T, Grünig E, Schmidt W, Herth FJF, Kreuter M. C-proSP-B: A Possible Biomarker for Pulmonary Diseases? **Respiration**. 2018;96(2):117-126.

**Kahn N**, Meister M, Eberhardt R, Muley T, Schnabel PA, Bender C, Johannes M, Keitel D, Sültmann H, Herth FJ, Kuner R. Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid. **J Thorac Oncol**. 2012 Jun;7(6):1001-8.

**Kahn N**, Kuner R, Eberhardt R, Meister M, Muley T, Winteroll S, Schnabel PA, Ishizaka A, Herth FJ, Poustka A, Sültmann H, Hoffmann H. Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. **J Thorac Cardiovasc Surg**. 2009 Aug;138(2):474-9.